Ascendis Pharma A/S (NASDAQ:ASND) Stock Position Trimmed by Ghost Tree Capital LLC

Ghost Tree Capital LLC lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) by 26.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,000 shares of the biotechnology company’s stock after selling 50,000 shares during the period. Ascendis Pharma A/S comprises 3.6% of Ghost Tree Capital LLC’s holdings, making the stock its 2nd largest position. Ghost Tree Capital LLC owned approximately 0.25% of Ascendis Pharma A/S worth $16,430,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ASND. SG Americas Securities LLC boosted its position in Ascendis Pharma A/S by 17.8% in the first quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 142 shares during the last quarter. Icapital Wealth LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $166,000. Bridgefront Capital LLC lifted its position in shares of Ascendis Pharma A/S by 32.2% during the 4th quarter. Bridgefront Capital LLC now owns 1,708 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 416 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $237,000. Finally, Envestnet Asset Management Inc. lifted its position in shares of Ascendis Pharma A/S by 14.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 282 shares during the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent research reports. Berenberg Bank reaffirmed a “buy” rating and set a $166.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, August 30th. Morgan Stanley dropped their price target on Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. SVB Leerink dropped their price target on Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Finally, Oppenheimer dropped their price target on Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $154.10.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $101.38 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 8.78 and a current ratio of 9.66. Ascendis Pharma A/S has a 52-week low of $61.58 and a 52-week high of $172.65. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of -12.85 and a beta of 0.66. The business’s fifty day moving average is $91.91 and its 200 day moving average is $96.77.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last announced its earnings results on Wednesday, August 10th. The biotechnology company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.57. The business had revenue of $6.51 million for the quarter, compared to analyst estimates of $7.07 million. Ascendis Pharma A/S had a negative return on equity of 48.92% and a negative net margin of 2,099.51%. Research analysts predict that Ascendis Pharma A/S will post -8.77 EPS for the current year.

Ascendis Pharma A/S Company Profile

(Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Read More

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASNDGet Rating).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.